T-PLL 2 study published

The phase 2 study for the treatment of T-PLL patients with a combined approach using the monoclonal antibody Alemtuzumab (anti-CD52) and FMC (fludarabine, mitoxantrone, and cyclophosphamide) has been published in Leukemia & Lymphoma. The prospective multi-center trial of the German CLL Study Group investigated the effects of a combined use of these two therapy lines on response, outcome and toxicity and built up on the T-PLL1 study.

Read the paper:
New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine–mitoxantrone–cyclophosphamide–alemtuzumab induction followed by alemtuzumab maintenance